Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
Polaryx Therapeutics announced its participation in the National Tay-Sachs & Allied Diseases Association Annual Family Conference to connect with patients and advocates while advancing its lead drug candidate, PLX-200, through the upcoming SOTERIA Phase 2 basket trial. This trial will evaluate PLX-200's safety and efficacy across several rare lysos…